Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emapalumab for the Prevention of Graft Rejection in HSCT Recipients
NCT07244419Phase 1Recruiting
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Jan 2026
- Primary completion
- Jun 2029
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of emapalumab in graft rejection (2 arms), sponsored by Cincinnati Children's Hospital Medical Center. Primary endpoint: Preliminary efficacy of Emapalumab at 100 days. Started Jan 2026; status: recruiting.
02
Drugs
emapalumab
03
Conditions
graft rejection
Beyond the preview
Go deeper on NCT07244419.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07244419.